These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 29520012)
1. Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis. van der Bent ML; Paulino da Silva Filho O; van Luijk J; Brock R; Wansink DG Sci Rep; 2018 Mar; 8(1):4181. PubMed ID: 29520012 [TBL] [Abstract][Full Text] [Related]
2. Dendrimer-Enabled Therapeutic Antisense Delivery Systems as Innovation in Medicine. Mignani S; Shi X; Zablocka M; Majoral JP Bioconjug Chem; 2019 Jul; 30(7):1938-1950. PubMed ID: 31246431 [TBL] [Abstract][Full Text] [Related]
4. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy. Relizani K; Goyenvalle A Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663 [TBL] [Abstract][Full Text] [Related]
6. Permeability of antisense oligonucleotide through porcine buccal mucosa. Jasti BR; Zhou S; Mehta RC; Li X Int J Pharm; 2000 Nov; 208(1-2):35-9. PubMed ID: 11064209 [TBL] [Abstract][Full Text] [Related]
7. Advanced Fluorescence Imaging to Distinguish Between Intracellular Fractions of Antisense Oligonucleotides. van der Bent ML; Wansink DG; Brock R Methods Mol Biol; 2020; 2063():119-138. PubMed ID: 31667767 [TBL] [Abstract][Full Text] [Related]
8. Opportunities and challenges for antisense oligonucleotide therapies. Kuijper EC; Bergsma AJ; Pijnappel WWMP; Aartsma-Rus A J Inherit Metab Dis; 2021 Jan; 44(1):72-87. PubMed ID: 32391605 [TBL] [Abstract][Full Text] [Related]
11. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides. White PJ; Anastasopoulos F; Pouton CW; Boyd BJ Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730 [TBL] [Abstract][Full Text] [Related]
12. Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy. van de Steeg E; Läppchen T; Aguilera B; Jansen HT; Muilwijk D; Vermue R; van der Hoorn JW; Donato K; Rossin R; de Visser PC; Vlaming MLH Nucleic Acid Ther; 2017 Aug; 27(4):221-231. PubMed ID: 28418733 [TBL] [Abstract][Full Text] [Related]
13. Opportunities and challenges for the development of antisense treatment in neuromuscular disorders. van Putten M; Aartsma-Rus A Expert Opin Biol Ther; 2011 Aug; 11(8):1025-37. PubMed ID: 21510827 [TBL] [Abstract][Full Text] [Related]
14. Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro. González-Barriga A; Nillessen B; Kranzen J; van Kessel IDG; Croes HJE; Aguilera B; de Visser PC; Datson NA; Mulders SAM; van Deutekom JCT; Wieringa B; Wansink DG Nucleic Acid Ther; 2017 Jun; 27(3):144-158. PubMed ID: 28375678 [TBL] [Abstract][Full Text] [Related]
15. Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides. Luna Velez MV; Paulino da Silva Filho O; Verhaegh GW; van Hooij O; El Boujnouni N; Brock R; Schalken JA Prostate; 2022 May; 82(6):657-665. PubMed ID: 35098567 [TBL] [Abstract][Full Text] [Related]